| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |